NCT06587542View on ClinicalTrials.gov

Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

September 15, 2025

Study Completion Date

December 31, 2025

Conditions
Anogenital WartsHIV InfectionTuberculin Purified Protein Derivative
Interventions
OTHER

Injection of protein purified derivative

Injection of purified protein derivative for anogenital warts in HIV and non HIV patient, on the largest lesion

All Listed Sponsors
lead

Universitas Padjadjaran

OTHER

NCT06587542 - Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient | Biotech Hunter | Biotech Hunter